Clinical trial NCT00445367: Biobank For MS And Other Demyelinating Diseases
Official title: Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Multiple Sclerosis
Transverse Myelitis
Neuromyelitis Optica
Acute Disseminated Encephalomyelitis
Optic Neuritis
Keywords: Multiple Sclerosis
Clinically Isolated Syndrome
Transverse Myelitis
Neuromyelitis Optica
Acute Disseminated Encephalomyelitis
Optic Neuritis
Repository
Biobank
Lead sponsor: Accelerated Cure Project for Multiple Sclerosis
Sponsor class: OTHER
First posted: 2007-03-09
Enrollment: 3226
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.

Brief summary: To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.


Eligibility criteria: Inclusion Criteria:

* age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
* willing to provide up to 110 ml (50 ml for \< 18 years old) of blood via venipuncture
* experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON

Exclusion Criteria:

* history of blood borne pathogens
* allogeneic bone marrow transplant
* clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
* weight less than 37 pounds

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Barrow Neurological Institute
state: Arizona
city: Stanford
country: United States
facility: Stanford University
state: California
city: Aurora
country: United States
facility: The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver
state: Colorado
city: Atlanta
country: United States
facility: Shepherd Center
state: Georgia
city: Baltimore
country: United States
facility: Johns Hopkins
state: Maryland
city: Boston
country: United States
facility: Beth Israel Deaconess
state: Massachusetts
city: Worcester
country: United States
facility: University of Massachusetts Medical School
state: Massachusetts
city: New York
country: United States
facility: Multiple Sclerosis Research Center of New York
state: New York
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center at Dallas
state: Texas
Study officials:
affiliation: University of Texas
name: Benjamin Greenberg, M.D., M.H.S.
role: PRINCIPAL_INVESTIGATOR
References: